Degenerative Arthritis Clinical Trial
Official title:
A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis
Verified date | November 2017 |
Source | Kolon Life Science |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether TissueGene-C, an allogeneic human chondrocytes expressing Transforming Growth Factor(TGF)-b1, is effective and safe in patients with degenerative arthritis.
Status | Completed |
Enrollment | 163 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female patients at least 19 years of age 2. Patients diagnosed with degenerative arthritis 3. Patients with IKDC(Knee Documentation Committee subjective score) score of 60 or below 4. Patients with 100 mm VAS(Visual Analog Scale) score of 40 or above 5. With Grade 3 osteoarthritis as determined by the radiographic criteria of Kellgren and Lawrence 6. With an International Cartilage Repair Society(ICRS) Grade III or IV cartilage damage in the major lesions, as confirmed through an MRI scan 7. With a Body Mass Index(BMI) of higher than18.5 and lower than 30 8. Patients who satisfies the clinical/radiational criteria by the American College of Rheumatology (ACR) guidelines, and applies to one of the following. - Older than 50 - Morning stiffness for less than 30 minutes - Crepitus and Osteophytes 9. With major lesions concentrated in one section of the knee, and with the major lesions considered the main cause of the clinical symptoms 10. With no alleviation of the symptoms even after at least three months of non-surgical treatment 11. Healthy, with no major findings from the physical examination, hematology, serum chemistry, and urine tests, and no significant medical history 12. Agreed to use an effective contraceptive method during the study period 13. Voluntarily agreed to participate in this study, and signed the informed consent form Exclusion Criteria: 1. Showed clinically significant hematology, serum chemistry, and urine test results at the screening visit 2. Regarding inclusion criteria 6. following patients should not be included - patients with a major lesion of ICRS grade 4 which is larger than 6cm2(for patient with ICRS grade 4) - patients with a major lesion of ICRS grade 3 which is larger than 6cm2(for patient without a ICRS grade 4), 3. Patient who had skin disease around target knee 4. patients who have a positive skin reaction to CS-10 5. Patients who had been administered with drugs such as oriental medicine, glucosamine and chondroitin within 14 days of baseline visit 6. Patients taking steroidal anti-inflammatory medications within 14 days of baseline visit 7. Patients with severe pain in other areas that could effect the diagnosis of the symptoms of the 8. History of surgery like arthroendoscopy within the past 6 months on the target knee 9. Patients who had been administered with immunosuppressants, including antirheumatic drugs (including methotrexate or antimetabolite), within the past 3 months 10. Patients who had been treated with physical therapy or herbal remedy (acupuncture, heat etc.) within 2 weeks of baseline visit 11. History of injection within the past 3 months on the target knee 12. Pregnant or breastfeeding female 13. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, synovial chondromas) 14. With an infectious disease, including HIV or hepatitis 15. With any of the following clinically significant diseases: - heart disease (e.g., myocardial infarction, arrhythmia, other serious heart diseases, coronary artery bypass graft) - kidney disease (e.g., chronic renal failure, glomerulonephritis) - liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease) - endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease) - insulin-dependent diabetes mellitus - medical history of past or current malignant tumor - In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests: - Leukemia (White Blood Cell level in the hematology) - Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma (Alkaline phosphatase level in the hematology) 16. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study 17. Patients who administered the TissueGene-C from past clinical trial 18. Considered inappropriate by the investigator for participation in this study |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Chungbuk National University Hospital | Cheongju | |
Korea, Republic of | Kyungpook National Univ. Hospital | Daegu | |
Korea, Republic of | Inha University Hospital | Incheon | |
Korea, Republic of | Chonbuk National University Hospital | Jeonju | |
Korea, Republic of | ASAN Medical Center | Seoul | |
Korea, Republic of | Ewha Womans University Mokdong Hospital | Seoul | |
Korea, Republic of | Hanyang University Medical Center | Seoul | |
Korea, Republic of | Inje University Seoul Paik Hospital | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | The Catholic University of Korea Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | Ulsan University Hospital | Ulsan |
Lead Sponsor | Collaborator |
---|---|
Kolon Life Science |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in IKDC scores | Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC) | Week 0 and 52 | |
Primary | Changes in 100 mm VAS scores | Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS) | Week 0 and 52 | |
Secondary | Changes in WOMAC scores | Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC) | Wekk 0, 26, 39 and 52 | |
Secondary | Changes in KOOS scores | Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS) | Week 0, 26, 39 and 52 | |
Secondary | Changes in MRI scan | Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 following dosing by an independent radiographic reviewer. | Week 0, 26 and 52 | |
Secondary | Changes in Joint Space Width by an independent radiographic reviewer. | Week 0, 26 and 52 | ||
Secondary | Level of Biomarkers in blood and urine. | Week 0, 26, 39 and 52 | ||
Secondary | Proportion of Patients Use of Rescue Medication. | Week 4, 12, 26, 39 and 52 | ||
Secondary | Changes in IKDC scores | Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC) | Week 0, 26 and 39 | |
Secondary | Changes in 100 mm VAS scores | Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS) | Week 0, 26 and 39 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02820766 -
Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting
|
N/A | |
Withdrawn |
NCT01308515 -
Vanguard Knee Anterior Stabilized Versus Posterior Stabilized Bearing Study
|
N/A | |
Terminated |
NCT03247023 -
Long Term Follow-up of Integra® Cadenceâ„¢ Total Ankle System in Primary Ankle Joint Replacement
|
||
Terminated |
NCT05357664 -
PINNACLE® DM RSA Study
|
N/A | |
Completed |
NCT01825811 -
Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis
|
Phase 2 | |
Terminated |
NCT01366989 -
INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation
|
N/A | |
Not yet recruiting |
NCT02286973 -
Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty
|
Phase 1 | |
Completed |
NCT01684371 -
The Effects of Elmore Oil on Patients With Osteoarthritis
|
N/A | |
Recruiting |
NCT00891501 -
The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects
|
Phase 2/Phase 3 | |
Completed |
NCT03000712 -
Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.
|
N/A | |
Withdrawn |
NCT04057885 -
To Determine the Gait and Functional Improvement in Total Knee Arthroplasty
|
N/A | |
Completed |
NCT04815070 -
Gastric Volume in Diabetic Patients Undergoing Staged Bilateral Total Knee Arthroplasty
|
||
Active, not recruiting |
NCT02038140 -
Zimmer Trabecular Metal Total Ankle PMCF
|
N/A | |
Recruiting |
NCT02469662 -
Clinical Outcomes Study of the Nexel Total Elbow
|
N/A | |
Terminated |
NCT00588887 -
Total Knee Replacement With Duracon® and Vanguardâ„¢ Prostheses
|
N/A | |
Completed |
NCT03990805 -
A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis
|
Phase 3 | |
Completed |
NCT02658344 -
Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis
|
Phase 2 | |
Completed |
NCT01671072 -
Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis
|
Phase 2 | |
Not yet recruiting |
NCT04821102 -
Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration
|
N/A | |
Terminated |
NCT02405234 -
Ascension PyroCarbon Radial Head Study
|
N/A |